AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2020

May 21, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2020-05-20

Reporting Person: Bowden Christopher (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-20	Common stock	M	3583	$35.16	Acquired	11889	Direct
2020-05-20	Common stock	S	3583	$50.014	Disposed	8306	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-20	Stock option (right to buy)	$35.16	M	3583	Disposed	2024-05-30	Common stock (3583.0)	Direct

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: Includes 76 shares purchased through the Company's employee stock purchase plan.

F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.05. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.